Effectiveness of Systane PRO for Mild to Moderate Dry Eye Disease

Part of paid clinical trials in La Jolla, California.

Sponsor
Gordon Schanzlin New Vision
Study ID
NCT07639034
Phase
PHASE4
Status
Completed

Conditions

  • Dry Eye Disease (DED)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Systane Pro Topical Ophthalmic — DRUG
    To show that consistent use of Systane PRO will significantly improve the signs and symptoms of Dry Eye Disease in patients with mild-moderate DED.

Study Details

The primary objective of this study is to show that consistent use of Systane PRO over a 30 period will significantly improve the signs and symptoms of Dry Eye Disease and decrease patients' ocular surface disease index score for patients diagnosed with mild-moderate (DED).

Key Dates

Start date
Nov 1, 2025
Status verified
Jun 2026
Primary completion
Feb 1, 2026
Completion
Feb 1, 2026

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: The Effectiveness of Systane PRO in providing relief from multiple symptoms of dry eye disease, and

Primary Outcome Measure

Change in Ocular Surface Disease Index (OSDI) Score From Baseline to Day 30 [ Time Frame: From enrollment to the end of participation at 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Gordon Schanzlin New Vision InstituteLa JollaCalifornia92037-

Find similar trials in La Jolla, CA

By research site
Gordon Schanzlin New Vision Institute· La Jolla, CA

Related Studies